189 related articles for article (PubMed ID: 16874485)
1. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients.
Benlalam H; Vignard V; Khammari A; Bonnin A; Godet Y; Pandolfino MC; Jotereau F; Dreno B; Labarrière N
Cancer Immunol Immunother; 2007 Apr; 56(4):515-26. PubMed ID: 16874485
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
3. Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.
Seiter S; Monsurro V; Nielsen MB; Wang E; Provenzano M; Wunderlich JR; Rosenberg SA; Marincola FM
J Immunother; 2002; 25(3):252-63. PubMed ID: 12000867
[TBL] [Abstract][Full Text] [Related]
4. PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.
Labarrière N; Gervois N; Bonnin A; Bouquié R; Jotereau F; Lang F
Cancer Immunol Immunother; 2008 Feb; 57(2):185-95. PubMed ID: 17646986
[TBL] [Abstract][Full Text] [Related]
5. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.
Benlalam H; Labarrière N; Linard B; Derré L; Diez E; Pandolfino MC; Bonneville M; Jotereau F
Eur J Immunol; 2001 Jul; 31(7):2007-15. PubMed ID: 11449353
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients.
Labarrière N; Pandolfino MC; Gervois N; Khammari A; Tessier MH; Dréno B; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):532-8. PubMed ID: 12384804
[TBL] [Abstract][Full Text] [Related]
8. Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.
Ramirez-Montagut T; Andrews DM; Ihara A; Pervaiz S; Pandolfi F; Van Den Elsen PJ; Waitkus R; Boyle LA; Hishii M; Kurnick JT
Clin Exp Immunol; 2000 Jan; 119(1):11-8. PubMed ID: 10606959
[TBL] [Abstract][Full Text] [Related]
9. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
10. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
Dréno B; Nguyen JM; Khammari A; Pandolfino MC; Tessier MH; Bercegeay S; Cassidanius A; Lemarre P; Billaudel S; Labarrière N; Jotereau F
Cancer Immunol Immunother; 2002 Nov; 51(10):539-46. PubMed ID: 12384805
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.
Adamina M; Bolli M; Albo F; Cavazza A; Zajac P; Padovan E; Schumacher R; Reschner A; Feder C; Marti WR; Oertli D; Heberer M; Spagnoli GC
Br J Cancer; 2004 Jan; 90(1):263-9. PubMed ID: 14710238
[TBL] [Abstract][Full Text] [Related]
13. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
14. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
Kawakami Y; Eliyahu S; Sakaguchi K; Robbins PF; Rivoltini L; Yannelli JR; Appella E; Rosenberg SA
J Exp Med; 1994 Jul; 180(1):347-52. PubMed ID: 7516411
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
Khammari A; Nguyen JM; Pandolfino MC; Quereux G; Brocard A; Bercegeay S; Cassidanius A; Lemarre P; Volteau C; Labarrière N; Jotereau F; Dréno B
Cancer Immunol Immunother; 2007 Nov; 56(11):1853-60. PubMed ID: 17549472
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
17. Tissue biomarkers in melanoma patients treated with TIL.
Knol AC; Nguyen JM; Pandolfino MC; Quéreux G; Brocard A; Peuvrel L; Saint-Jean M; Saiagh S; Khammari A; Dréno B
PLoS One; 2012; 7(12):e48729. PubMed ID: 23284620
[TBL] [Abstract][Full Text] [Related]
18. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.
Panelli MC; Riker A; Kammula U; Wang E; Lee KH; Rosenberg SA; Marincola FM
J Immunol; 2000 Jan; 164(1):495-504. PubMed ID: 10605047
[TBL] [Abstract][Full Text] [Related]
19. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
20. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.
Gervois N; Guilloux Y; Diez E; Jotereau F
J Exp Med; 1996 May; 183(5):2403-7. PubMed ID: 8642353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
